创新药企ETF(560900)盘中涨超1.5%，冲击4连涨，创新药BD高潮迭起，机构持续看好中国资产潜力

Group 1 - The innovative drug ETF (560900) has shown active upward movement, with a rise of over 1.5% in early trading, marking a four-day consecutive increase [1] - The index it tracks, the CSI Innovative Drug Industry Index (931152), increased by 0.65%, with notable gains from constituent stocks such as Tigermed (300347) up 5.29% and Kelun Pharmaceutical (002422) up 3.90% [1] - According to Debon Securities, the innovative drug sector in China is experiencing robust growth supported by policies, funding, talent return, and engineering advantages, with the number of original innovative drugs rapidly increasing from 124 in 2015 to 704 in 2024, leading globally [1] Group 2 - The CSI Innovative Drug Industry Index selects up to 50 representative listed companies involved in innovative drug research and development to reflect the overall performance of the innovative drug sector [2] - Morgan Asset Management is integrating its "Global Vision Investment Technology" product line to help investors capitalize on quality technology companies amid a new wave of technological advancements driven by AI [2] - Various actively managed funds by Morgan focus on emerging industry trends, AI opportunities, and sectors like new energy vehicles and humanoid robots [2] Group 3 - Morgan's passive investment options include the Morgan Hang Seng Technology ETF and the Morgan CSI Innovative Drug Industry ETF, which provide one-click access to Hong Kong tech assets and Chinese innovative drug companies, respectively [3]